GAGE2E Inhibitors
GAGE2E inhibitors represent a class of chemical compounds that exert their effects by impeding specific signaling pathways and biological processes that GAGE2E is involved in, leading to a decrease in the protein's functional activity. These inhibitors work through a variety of mechanisms, each tailored to a particular aspect of cellular signaling. For example, certain inhibitors in this class target protein kinases, which GAGE2E may rely on for its activation or stability. By inhibiting these kinases, the phosphorylation of GAGE2E is reduced, thus decreasing its activity within the cell. Furthermore, some compounds are designed to disrupt pathways such as the PI3K/Akt or MAPK/ERK cascades. Since these pathways are integral to the regulation of cell survival, proliferation, and differentiation, any modulation in their signaling can lead to a suppression of GAGE2E function if it is a downstream effector.
Other inhibitors focus on stress-responsive pathways, like the p38 MAP kinase and JNK signaling pathways. These are crucial in mediating inflammatory responses and apoptosis, and if GAGE2E is implicated in such pathways, its inhibition would result in reduced GAGE2E activity. Additionally, some inhibitors act as antagonists to calmodulin, thereby influencing calcium signaling within the cell. If GAGE2E's activity is contingent upon calcium/calmodulin-dependent processes, blocking calmodulin would naturally lead to a decrease in GAGE2E's activity. Inhibition of Ca2+/calmodulin-dependent protein kinase II also represents a potential mechanism to decrease GAGE2E activity, assuming a regulatory relationship exists. Lastly, compounds that inhibit protein kinase C can alter GAGE2E activity by affecting PKC-mediated signaling pathways, which could be crucial for the functional expression of GAGE2E.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that targets a wide range of kinases which are important in various signaling pathways. Through its broad spectrum activity, it inhibits phosphorylation events that are crucial for GAGE2E's functional activity within any kinase-dependent signaling cascades it may be a part of. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of the PI3k/Akt pathway which is involved in cell survival and proliferation. By inhibiting this pathway, LY294002 could lead to reduced activity of downstream targets that are crucial for the functional activity of GAGE2E. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that affects the mTORC1 complex, leading to a downregulation of cellular processes including those that could be necessary for GAGE2E's activity. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
A glucose transporter 1 (GLUT1) inhibitor that disrupts cellular glucose uptake, affecting energy metabolism and signaling pathways that are essential for GAGE2E function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK, which specifically blocks the MAPK/ERK pathway. This inhibition could lead to an indirect decrease in GAGE2E activity given GAGE2E functions are dependent on the MAPK/ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A specific inhibitor of p38 MAPK which by inhibiting the p38 MAPK pathway could affect downstream processes that are vital for the functional activity of GAGE2E. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is involved in the stress-activated MAPK pathway. Inhibition of JNK could lead to reduced activity of any JNK-dependent signaling that is necessary for GAGE2E functionality. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins, leading to altered signaling pathways and cellular stress responses that are crucial for GAGE2E activity. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
An Aurora kinase inhibitor which can disrupt cell cycle progression and signaling pathways that may be essential for GAGE2E function. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
A selective inhibitor of protein kinase C (PKC) which is involved in various signaling pathways. Inhibition of PKC could lead to a decrease in GAGE2E activity given GAGE2E is regulated through PKC-dependent signaling. | ||||||